Skip to main
HOLX

Hologic (HOLX) Stock Forecast & Price Target

Hologic (HOLX) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 18%
Hold 64%
Sell 0%
Strong Sell 0%

Bulls say

Hologic is positioned for strong growth, with expectations of 5-7% organic revenue growth driven by robust procedure volume increases, new product launches, and strategic acquisitions. The company’s ongoing improvements in Diagnostics and Breast Health segments may lead to accelerated revenue growth in the high-single digits, with potential for enhanced operating margins and significant earnings growth of 8-12%. Additionally, Hologic's strong balance sheet and low leverage provide a solid foundation for continued margin expansion and favorable business trends moving forward.

Bears say

Hologic's stock faces a negative outlook primarily due to anticipated revenue growth slowing to low-single digits (1-4%), predominantly attributed to weakness in its Diagnostics and Breast Health segments. The company's performance has been disappointing, with only 9.4% and 4.4% returns over the past three and five years, respectively, and further growth potential appears limited amid softening demand and increased competition. Additionally, the challenges posed by a weak global economy, integration difficulties from recent acquisitions, and the likelihood of stagnating operating margins indicate significant risk to Hologic's future earnings potential.

Hologic (HOLX) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 18% recommend Buy, 64% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hologic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hologic (HOLX) Forecast

Analysts have given Hologic (HOLX) a Hold based on their latest research and market trends.

According to 11 analysts, Hologic (HOLX) has a Hold consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $78.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $78.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hologic (HOLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.